Mydipin5 mg

Established Use

Mydipin is indicated for the treatment of essential hypertension (high blood pressure) in adults. It is used to lower blood pressure and, by doing so, reduce the risk of hypertension-related complications such as stroke and cardiovascular events.

Guideline-Supported / Preferential Use

Mydipin is particularly favored in hypertensive patients who also have diabetes mellitus, albuminuria (protein in urine), or chronic kidney disease, because its additional N-type calcium channel blocking action may offer a degree of renal protection and reduced glomerular capillary pressure compared with conventional dihydropyridine calcium channel blockers. It may also be preferred in patients prone to reflex tachycardia or sympathetic activation on standard dihydropyridine calcium channel blockers.

Combination Therapy

In patients whose blood pressure is not adequately controlled on Mydipin alone, it may be combined with other antihypertensive classes such as angiotensin receptor blockers (ARBs), ACE inhibitors, or diuretics, under physician supervision.

Each tablet contains Cilnidipine as the active ingredient, commonly available in strengths of 5 mg and 10 mg for oral administration.

Tablets also contain standard pharmaceutical excipients such as fillers, binders, and coating agents, which vary by manufacturer.

Mydipin is a fourth-generation dihydropyridine calcium channel blocker used in the management of hypertension. Unlike most conventional dihydropyridine calcium channel blockers (such as amlodipine or nifedipine), which act only on L-type calcium channels in vascular smooth muscle, Mydipin is distinguished by its dual blockade of both L-type and N-type calcium channels.

This dual mechanism allows Mydipin to produce vasodilation (via L-type channel blockade) while also suppressing sympathetic nerve-mediated norepinephrine release (via N-type channel blockade at sympathetic nerve terminals). As a result, Mydipin is associated with less reflex tachycardia and, in some studies, less peripheral edema compared with typical dihydropyridine calcium channel blockers, although the comparative degree of benefit should be interpreted with caution and individual response may vary.

Cilnidipine is a dihydropyridine calcium channel blocker with a dual mechanism of action:

• L-type calcium channel blockade: Cilnidipine inhibits calcium influx through L-type voltage-dependent calcium channels in vascular smooth muscle, producing arterial vasodilation and lowering peripheral vascular resistance, which reduces blood pressure.
• N-type calcium channel blockade: Cilnidipine also inhibits calcium influx through N-type voltage-dependent calcium channels located in sympathetic nerve terminals. This suppresses norepinephrine release, which blunts the sympathetic nervous system activation and reflex tachycardia that typically accompany vasodilation with conventional (L-type-selective) dihydropyridine calcium channel blockers.

This combined action gives Cilnidipine a smoother antihypertensive effect with a theoretically favorable heart-rate and renal hemodynamic profile compared with L-type-selective agents, though individual clinical response varies and comparative claims should not be overstated.

Pharmacokinetics: Cilnidipine is well absorbed after oral administration, is highly bound to plasma proteins, and is extensively metabolized in the liver via the cytochrome P450 (CYP3A4) pathway before being eliminated, mainly through feces with a smaller renal component. Its onset of action following oral dosing is gradual, consistent with a once-daily dosing regimen.

Mydipin tablets should be swallowed whole with a glass of water, preferably after breakfast, at the same time each day. It should not be crushed or chewed unless the product labeling specifically permits it. Mydipin may be taken with or without food, but taking it after a meal, particularly breakfast, is generally recommended for consistency. Avoid taking Mydipin with grapefruit or grapefruit juice (see Interactions).

Other Antihypertensive Agents

Concomitant use of Mydipin with other blood-pressure-lowering medications (e.g., ARBs, ACE inhibitors, diuretics, beta-blockers) or with drugs that can cause hypotension (e.g., certain antipsychotics) may result in an additive drop in blood pressure. Dose adjustment and monitoring are recommended.

CYP3A4 Inhibitors

Mydipin is metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors such as erythromycin, cimetidine, or certain antifungal agents can increase plasma levels of Mydipin and enhance its blood-pressure-lowering and side-effect profile. Grapefruit juice contains CYP3A4-inhibiting compounds and can similarly raise Mydipin plasma concentrations, a recognized class effect of dihydropyridine calcium channel blockers; grapefruit and grapefruit juice should be avoided during treatment with Mydipin.

CYP3A4 Inducers

Strong CYP3A4 inducers such as rifampicin, carbamazepine, and phenytoin may reduce plasma levels of Mydipin and diminish its antihypertensive effect; blood pressure should be monitored if these are co-administered.

Quinidine

Concurrent use with quinidine has been reported to interact with dihydropyridine calcium channel blockers including Mydipin; caution and monitoring are advised.

Side effects of Mydipin are generally mild to moderate and dose-related, consistent with its vasodilatory calcium channel blocking action.

Common

• Dizziness
• Flushing
• Headache
• Palpitations
• Peripheral (ankle) edema
• Increased frequency of urination (nocturnal/daytime)

Less Common

• Gastrointestinal disturbances (nausea, dyspepsia, constipation)
• Lethargy or fatigue
• Gum hyperplasia (rare, class effect of dihydropyridines)
• Elevated liver enzymes (rare)

Patients should seek medical advice if side effects are persistent, severe, or accompanied by symptoms such as fainting, chest pain, or significant swelling.

Pregnancy: The safety of Mydipin in human pregnancy has not been well established. Mydipin should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus. Many experts advise avoiding Mydipin during pregnancy in favor of antihypertensives with a more established safety record, and it should generally be avoided unless no suitable alternative is available; a physician should always be consulted.

Lactation: It is not well established whether Mydipin passes into human breast milk. Because of the potential for adverse effects in a nursing infant, a decision should be made to discontinue breastfeeding or discontinue Mydipin, taking into account the importance of the drug to the mother, in consultation with a physician.

Hepatic Impairment

Mydipin is extensively metabolized by the liver. Use with caution in patients with hepatic impairment, as plasma concentrations may be increased; avoid use in severe hepatic dysfunction unless a physician determines the benefit outweighs the risk, with close monitoring.

Hypotension

Mydipin can cause symptomatic hypotension, particularly when combined with other antihypertensive agents, in elderly patients, or in volume-depleted patients. Blood pressure should be monitored, especially at treatment initiation or dose escalation.

Grapefruit Juice

Avoid grapefruit and grapefruit juice during treatment with Mydipin, as they can increase plasma levels of Mydipin through CYP3A4 inhibition (see Interactions).

Peripheral Edema

Dose-dependent peripheral edema can occur with Mydipin, as with other dihydropyridine calcium channel blockers; it may be less pronounced than with some other agents in this class, though this comparative effect should not be assumed for every individual patient.

Cardiac Disease

Use with caution in patients with severe aortic stenosis, unstable angina, or recent myocardial infarction, as data in these populations are limited.

Discontinuation

Do not stop Mydipin abruptly without medical advice; dosage should be reduced gradually under physician supervision if discontinuation is required.

Overdose of Mydipin can cause excessive peripheral vasodilation leading to pronounced and prolonged hypotension, reflex or, less commonly, bradycardia, dizziness, and possibly shock. In case of suspected Mydipin overdose, seek immediate medical attention or contact a poison control center right away. Management is supportive and should be carried out in a hospital setting under medical supervision, which may include cardiovascular monitoring, intravenous fluids, and vasopressor support as clinically indicated; do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Elderly patients should be started on the lowest dose of Mydipin (5 mg once daily) due to increased susceptibility to hypotension, with cautious dose titration and monitoring.

Renal Impairment

Mydipin may be used with caution in patients with renal impairment; because of its potentially favorable renal hemodynamic profile it is sometimes preferred in hypertensive patients with chronic kidney disease, but blood pressure and renal function should be monitored.

Hepatic Impairment

See Precautions and Warnings — caution advised, avoid in severe hepatic impairment.

Pediatric Patients

Safety and efficacy of Mydipin in children have not been established; see Pediatric Uses.

Mydipin is generally used as a long-term, chronic therapy for hypertension, often continued indefinitely to maintain blood pressure control, unless the treating physician decides otherwise based on response, tolerability, or changes in clinical status. Blood pressure and overall response should be reviewed periodically by the prescribing physician.

Calcium Channel Blockers (Dihydropyridine derivatives) — Antihypertensives

Cilnidipine blocks both L-type calcium channels in vascular smooth muscle (producing vasodilation and reduced blood pressure) and N-type calcium channels in sympathetic nerve terminals (reducing norepinephrine release and sympathetic activation), giving it a dual mechanism distinct from conventional dihydropyridine calcium channel blockers that act on L-type channels alone.

The safety and efficacy of Mydipin in pediatric patients (under 18 years of age) have not been established. Mydipin is therefore not recommended for use in children, and its use in this population should be avoided unless specifically directed by a pediatric specialist in exceptional circumstances.